Pictured from left to right: FNIH Chair Dr. Steven Paul, Amgen CEO Bob Bradway, FNIH CEO Dr. Julie Gerberding, and former National Institutes of Health Director Dr. Francis Collins.


Amgen Honored by Foundation of National Institutes of Health

CEO Bob Bradway accepted the Charles A. Sanders, M.D. Partnership Award in recognition of our collaborations with FNIH over many years to advance science and improve health.

Amgen has earned the prestigious Charles A. Sanders, M.D. Partnership Award from the Foundation of the National Institutes of Health (FNIH). Former NIH Director Francis Collins, M.D., was a co-recipient along with Amgen of this year’s Partnership Award, which recognizes individuals and organizations that have made significant contributions to the FNIH’s work in support of the mission of the National Institutes of Health. Past recipients include Pfizer, the Bill and Melinda Gates Foundation, and Anthony Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases.

Amgen received the 2022 Charles A. Sanders, M.D. Partnership Award in recognition of the company’s long-time support of FNIH initiatives to advance science in therapeutic categories such as cancer and heart disease. Additionally, Amgen has been a flagship sponsor of an FNIH program focused on improving women’s health, while the Amgen Foundation has supported 125 Amgen Scholars at the NIH since 2015.

“The FNIH’s partnerships bring together the public and private sectors to advance groundbreaking biomedical research,” said Julie L. Gerberding, MD, CEO of the FNIH. “Dr. Francis Collins and Amgen represent the best of our partners interested in working collaboratively to improve the lives of patients.”

CEO Bob Bradway accepted the Partnership Award on Amgen’s behalf at the FNIH’s annual awards dinner, held in Washington, D.C. on October 19. “Amgen’s work with the FNIH is an outstanding example of partnership in service of innovation,” Bradway remarked. “Today, technology and biotechnology are converging in ways that enhance our ability to bring more innovative medicines to more patients, faster than ever before. The FNIH is playing a vital role in making those advances possible, and all of us at Amgen are proud to support your work.”

Share This Story